Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Investigation to Evaluate the New Health Sciences Hemanext® Oxygen Reduction System for Leukoreduced Red Blood Cells With CP2D Anticoagulant and AS-3 Additive - Pivotal Trial

NCT03301779 is registered in ClinicalTrials.gov with Hemanext as lead sponsor.

NCT NCT03301779
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03301779 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Investigation to Evaluate the New Health Sciences Hemanext® Oxygen Reduction System for Leukoreduced Red Blood Cells With CP2D Anticoagulant and AS-3 Additive - Pivotal Trial
Lead sponsor
Hemanext
Phase
Phase 2
Overall status
Completed
Start date
November 27, 2017
Completion date
March 6, 2019
Enrollment
100 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

whole blood donation and leukoreduction